Day TwoTuesday, 20 May 2025 - ET (Eastern Time, GMT-05:00)

• How vertical integration changes historical business models across payers, providers, and pharma

• Impact of policy changes on drug development and commercialization decisions

• Future scenarios for pricing models given IRA implementation

• Balancing innovation with market access in evolving landscape

• Analyze how FTC investigations, proposed rules and transparency initiatives are reshaping PBM business models and stakeholder relationships across the healthcare ecosystem
• Understand the transformation from traditional cost management to today's integrated marketplace through unique insights from executives with both PBM and manufacturer experience
• Discover collaborative approaches for manufacturers and PBMs to navigate new regulatory requirements while balancing market access, patient needs and system sustainability

• Exploring data transparency initiatives between manufacturers and covered entities
• Building effective partnerships between stakeholders to prevent duplicate discounts
• Balancing program sustainability with expanding access

• Aligning pricing strategy with contracting execution across organization
• Integrating market access planning with government program requirements
• Coordinating finance, legal and operations for effective decision-making
• Building communication frameworks between commercial and government teams

• Creating effective dialogue between manufacturers, PBMs, and payers on market access
• Developing partnerships with CMS and state agencies for program implementation
• Working with patient advocacy groups to understand access challenges
• Building sustainable relationships with GPOs and wholesalers for mutual success

• Share leading practices in good-faith inquiries

• Understand the guidelines for manufacturer audits and the dispute resolution process

• Review results of recent HRSA audits of manufacturers and covered entities

• Describe the process for developing and implementing a successful corrective action plan (CAP)

• How major teaching hospitals are adapting inventory and contract pharmacy strategies amid program changes
• Real patient impact stories and access challenges from a hospital executive lens
• Operational realities: A candid look at hospital data management, compliance, and manufacturer partnerships

• Analysis of J&J's rebate model shift and HRSA's response: Implications for the broader industry and potential program changes
• State actions affecting contract pharmacy restrictions and program implementation
• Updates on Supreme Court deliberations and pending litigation affecting the 340B landscape

This interactive open forum invites active participation from all 340B stakeholders. The moderator will guide the discussion, ensuring balanced representation of diverse perspectives. Attendees will share experiences, pain points, and proposed solutions to foster collaborative dialogue and drive positive transformation for the 340B program. By convening this collaborative forum, the session aims to build bridges, uncover innovative ideas, and equip attendees with the knowledge and tools to navigate the evolving 340B landscape.

• Understand how AIDS Drug Assistance Programs operate differently from typical 340B covered entities, focusing on unique rebate structures versus traditional chargeback models
• Navigate the specific requirements for manufacturers engaging with ADAP programs, including contract management, rebate processing, and program compliance
• Learn best practices for managing ADAP relationships, from initial program setup through ongoing operations and reporting requirements